Send us a Message



Submit Data |  Help |  Video Tutorials |  News |  Publications |  Download |  REST API |  Citing RGD |  Contact   

CHEBI ONTOLOGY - ANNOTATIONS

The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.

Term:fibroblast growth factor receptor antagonist
go back to main search page
Accession:CHEBI:63457 term browser browse the term
Definition:An antagonist at the fibroblast growth factor receptor.
Synonyms:related_synonym: FGFR inhibitor;   FGFR inhibitors;   fibroblast growth factor receptor antagonists;   fibroblast growth factor receptor inhibitor;   fibroblast growth factor receptor inhibitors



show annotations for term's descendants           Sort by:
 
AZD4547 term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Akt1 AKT serine/threonine kinase 1 decreases phosphorylation ISO AZD4547 results in decreased phosphorylation of AKT1 protein CTD PMID:26853465 NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921
JBrowse link
G Akt1s1 AKT1 substrate 1 decreases phosphorylation ISO AZD4547 results in decreased phosphorylation of AKT1S1 protein CTD PMID:26853465 NCBI chr 1:95,333,186...95,339,678
Ensembl chr 1:95,332,898...95,339,677
JBrowse link
G Frs2 fibroblast growth factor receptor substrate 2 increases phosphorylation ISO AZD4547 results in increased phosphorylation of FRS2 protein CTD PMID:26853465 NCBI chr 7:52,711,255...52,792,758
Ensembl chr 7:52,711,257...52,792,743
JBrowse link
G Map1lc3b microtubule-associated protein 1 light chain 3 beta affects expression
multiple interactions
ISO AZD4547 affects the expression of MAP1LC3B protein modified form
bafilomycin A1 affects the reaction [AZD4547 affects the expression of MAP1LC3B protein modified form]
CTD PMID:26853465 NCBI chr19:49,665,795...49,673,655
Ensembl chr19:49,665,791...49,677,690
JBrowse link
G Rps6 ribosomal protein S6 decreases phosphorylation ISO AZD4547 results in decreased phosphorylation of RPS6 protein CTD PMID:26853465 NCBI chr 5:101,371,716...101,374,576
Ensembl chr 5:101,371,136...101,374,602
Ensembl chr 5:101,371,136...101,374,602
JBrowse link
G Srebf1 sterol regulatory element binding transcription factor 1 decreases expression ISO AZD4547 results in decreased expression of SREBF1 protein CTD PMID:26853465 NCBI chr10:45,007,637...45,029,650
Ensembl chr10:45,007,637...45,029,650
JBrowse link
lenvatinib term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Atp5f1a ATP synthase F1 subunit alpha affects expression EXP lenvatinib affects the expression of ATP5F1A protein CTD PMID:34019861 NCBI chr18:71,292,406...71,300,342
Ensembl chr18:71,292,374...71,300,794
JBrowse link
G Cat catalase decreases expression EXP lenvatinib results in decreased expression of CAT mRNA CTD PMID:34019861 NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478
JBrowse link
G Cdkn1a cyclin-dependent kinase inhibitor 1A affects expression EXP lenvatinib affects the expression of CDKN1A protein CTD PMID:34019861 NCBI chr20:7,149,177...7,159,727
Ensembl chr20:7,149,217...7,159,585
JBrowse link
G Dnm1l dynamin 1-like increases expression EXP lenvatinib results in increased expression of DNM1L mRNA CTD PMID:34019861 NCBI chr11:84,581,216...84,632,382
Ensembl chr11:84,581,216...84,631,482
JBrowse link
G Fis1 fission, mitochondrial 1 increases expression EXP lenvatinib results in increased expression of FIS1 mRNA CTD PMID:34019861 NCBI chr12:19,708,558...19,723,392
Ensembl chr12:19,708,558...19,723,377
JBrowse link
G Lonp1 lon peptidase 1, mitochondrial decreases expression EXP lenvatinib results in decreased expression of LONP1 protein CTD PMID:34019861 NCBI chr 9:1,447,444...1,459,771
Ensembl chr 9:1,447,447...1,459,771
JBrowse link
G Map3k5 mitogen-activated protein kinase kinase kinase 5 increases expression EXP lenvatinib results in increased expression of MAP3K5 mRNA CTD PMID:34019861 NCBI chr 1:14,685,776...14,904,935
Ensembl chr 1:14,685,492...14,904,800
JBrowse link
G Mapk8 mitogen-activated protein kinase 8 increases expression EXP lenvatinib results in increased expression of MAPK8 mRNA CTD PMID:34019861 NCBI chr16:8,638,897...8,721,960
Ensembl chr16:8,638,924...8,721,981
JBrowse link
G Mfn1 mitofusin 1 affects expression EXP lenvatinib affects the expression of MFN1 mRNA CTD PMID:34019861 NCBI chr 2:115,313,380...115,359,651
Ensembl chr 2:115,313,401...115,359,640
JBrowse link
G Mfn2 mitofusin 2 affects expression EXP lenvatinib affects the expression of MFN2 mRNA CTD PMID:34019861 NCBI chr 5:158,304,285...158,335,502
Ensembl chr 5:158,304,287...158,335,342
JBrowse link
G Mt-co1 mitochondrially encoded cytochrome c oxidase I affects expression EXP lenvatinib affects the expression of COX1 protein CTD PMID:34019861 NCBI chr MT:5,323...6,867
Ensembl chr MT:5,323...6,867
JBrowse link
G Ndufb8 NADH:ubiquinone oxidoreductase subunit B8 affects expression EXP lenvatinib affects the expression of NDUFB8 protein CTD PMID:34019861 NCBI chr 1:243,408,659...243,413,701
Ensembl chr 1:243,408,619...243,413,817
JBrowse link
G Nfe2l2 NFE2 like bZIP transcription factor 2 decreases expression EXP lenvatinib results in decreased expression of NFE2L2 mRNA CTD PMID:34019861 NCBI chr 3:60,594,239...60,621,785
Ensembl chr 3:60,594,242...60,621,737
JBrowse link
G Nrf1 nuclear respiratory factor 1 affects expression EXP lenvatinib affects the expression of NRF1 mRNA CTD PMID:34019861 NCBI chr 4:58,664,932...58,772,328
Ensembl chr 4:58,664,957...58,825,328
JBrowse link
G Opa1 OPA1, mitochondrial dynamin like GTPase increases expression EXP lenvatinib results in increased expression of OPA1 mRNA CTD PMID:34019861 NCBI chr11:71,108,100...71,185,170
Ensembl chr11:71,109,873...71,185,109
JBrowse link
G Sdhb succinate dehydrogenase complex iron sulfur subunit B decreases expression EXP lenvatinib results in decreased expression of SDHB protein CTD PMID:34019861 NCBI chr 5:153,264,906...153,285,570
Ensembl chr 5:153,264,899...153,314,293
JBrowse link
G Sod2 superoxide dismutase 2 increases expression EXP lenvatinib results in increased expression of SOD2 mRNA CTD PMID:34019861 NCBI chr 1:47,638,318...47,645,163
Ensembl chr 1:47,636,528...47,645,189
JBrowse link
G Ucp2 uncoupling protein 2 decreases expression EXP lenvatinib results in decreased expression of UCP2 mRNA; lenvatinib results in decreased expression of UCP2 protein CTD PMID:34019861 NCBI chr 1:154,839,242...154,845,612
Ensembl chr 1:154,839,209...154,845,611
JBrowse link
G Uqcrc2 ubiquinol cytochrome c reductase core protein 2 affects expression EXP lenvatinib affects the expression of UQCRC2 protein CTD PMID:34019861 NCBI chr 1:175,167,933...175,198,499
Ensembl chr 1:175,167,894...175,199,453
JBrowse link
nintedanib term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Tuba1a tubulin, alpha 1A decreases expression ISO nintedanib results in decreased expression of TUBA1A mRNA CTD PMID:27015953 NCBI chr 7:130,113,214...130,116,880
Ensembl chr 7:130,081,032...130,196,186
JBrowse link
PD173074 term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Birc5 baculoviral IAP repeat-containing 5 multiple interactions ISO [arsenic trioxide results in increased susceptibility to PD 173074] which results in decreased expression of BIRC5 protein CTD PMID:27794399 NCBI chr10:103,072,530...103,081,382
Ensembl chr10:103,073,408...103,081,380
JBrowse link
G Ccnd1 cyclin D1 multiple interactions ISO [PKI 166 co-treated with PD 173074] results in decreased expression of CCND1 protein CTD PMID:15377668 NCBI chr 1:200,089,002...200,098,524
Ensembl chr 1:200,089,002...200,098,602
JBrowse link
G Fgf1 fibroblast growth factor 1 multiple interactions ISO PD 173074 inhibits the reaction [FGF1 protein results in increased phosphorylation of FGFR4 protein] CTD PMID:15709206 NCBI chr18:30,686,555...30,772,667
Ensembl chr18:30,686,581...30,772,357
JBrowse link
G Fgfr1 Fibroblast growth factor receptor 1 decreases activity
decreases expression
multiple interactions
ISO PD 173074 results in decreased activity of FGFR1 protein
PD 173074 results in decreased expression of FGFR1 protein
[PD 173074 results in decreased activity of FGFR1 protein] inhibits the reaction [[Crizotinib results in decreased phosphorylation of MET protein] which results in increased expression of HGF protein]; Arsenic Trioxide promotes the reaction [PD 173074 results in decreased expression of FGFR1 protein]; PD 173074 promotes the reaction [Arsenic Trioxide results in decreased expression of FGFR1 protein]
CTD PMID:22683780 PMID:27794399 NCBI chr16:66,492,445...66,546,731
Ensembl chr16:66,494,042...66,547,350
JBrowse link
G Fgfr3 fibroblast growth factor receptor 3 decreases activity ISO PD 173074 results in decreased activity of FGFR3 protein CTD PMID:15029211 NCBI chr14:76,987,242...77,002,671
Ensembl chr14:76,987,993...77,003,341
JBrowse link
G Fgfr4 fibroblast growth factor receptor 4 multiple interactions
decreases activity
ISO PD 173074 inhibits the reaction [FGF1 protein results in increased phosphorylation of FGFR4 protein]
PD 173074 results in decreased activity of FGFR4 protein
CTD PMID:15377668 PMID:15709206 NCBI chr17:9,461,541...9,476,268
Ensembl chr17:9,461,547...9,476,242
JBrowse link
G Hgf hepatocyte growth factor multiple interactions ISO [PD 173074 results in decreased activity of FGFR1 protein] inhibits the reaction [[crizotinib results in decreased phosphorylation of MET protein] which results in increased expression of HGF protein] CTD PMID:22683780 NCBI chr 4:18,673,736...18,745,582
Ensembl chr 4:18,677,101...18,745,409
JBrowse link
G Mapk1 mitogen activated protein kinase 1 decreases phosphorylation
decreases expression
multiple interactions
ISO PD 173074 results in decreased phosphorylation of MAPK1 protein
PD 173074 results in decreased expression of MAPK1 protein
PD 173074 inhibits the reaction [PHLPP1 gene mutant form results in increased phosphorylation of MAPK1 protein]
CTD PMID:15029211 PMID:25953896 PMID:27794399 NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616
JBrowse link
G Mapk3 mitogen activated protein kinase 3 decreases phosphorylation
decreases expression
multiple interactions
ISO PD 173074 results in decreased phosphorylation of MAPK3 protein
PD 173074 results in decreased expression of MAPK3 protein
PD 173074 inhibits the reaction [PHLPP1 gene mutant form results in increased phosphorylation of MAPK3 protein]
CTD PMID:15029211 PMID:25953896 PMID:27794399 NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863
JBrowse link
G Met MET proto-oncogene, receptor tyrosine kinase multiple interactions ISO [PD 173074 results in decreased activity of FGFR1 protein] inhibits the reaction [[crizotinib results in decreased phosphorylation of MET protein] which results in increased expression of HGF protein] CTD PMID:22683780 NCBI chr 4:45,790,456...45,898,139
Ensembl chr 4:45,790,791...45,897,876
JBrowse link
G Parp1 poly (ADP-ribose) polymerase 1 multiple interactions ISO [arsenic trioxide co-treated with PD 173074] results in increased expression of PARP1 protein modified form; [arsenic trioxide results in increased susceptibility to PD 173074] which results in increased expression of PARP1 protein modified form; [PD 173074 results in increased susceptibility to arsenic trioxide] which results in increased expression of PARP1 protein modified form CTD PMID:27794399 NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404
JBrowse link
G Phlpp1 PH domain and leucine rich repeat protein phosphatase 1 multiple interactions ISO PD 173074 inhibits the reaction [PHLPP1 gene mutant form results in increased phosphorylation of MAPK1 protein]; PD 173074 inhibits the reaction [PHLPP1 gene mutant form results in increased phosphorylation of MAPK3 protein] CTD PMID:25953896 NCBI chr13:22,308,532...22,530,978
Ensembl chr13:22,308,548...22,530,977
JBrowse link
G Raf1 Raf-1 proto-oncogene, serine/threonine kinase decreases expression
multiple interactions
ISO PD 173074 results in decreased expression of RAF1 protein; PD 173074 results in decreased expression of RAF1 protein modified form
[arsenic trioxide co-treated with PD 173074] results in decreased expression of RAF1 protein; [arsenic trioxide co-treated with PD 173074] results in decreased expression of RAF1 protein modified form; [arsenic trioxide results in increased susceptibility to PD 173074] which results in decreased expression of RAF1 protein; [PD 173074 results in increased susceptibility to arsenic trioxide] which results in decreased expression of RAF1 protein; [PD 173074 results in increased susceptibility to arsenic trioxide] which results in decreased expression of RAF1 protein modified form; arsenic trioxide promotes the reaction [PD 173074 results in decreased expression of RAF1 protein modified form]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [[arsenic trioxide co-treated with PD 173074] results in decreased expression of RAF1 protein modified form]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [[arsenic trioxide co-treated with PD 173074] results in decreased expression of RAF1 protein]
CTD PMID:27794399 NCBI chr 4:148,679,534...148,740,265
Ensembl chr 4:148,679,530...148,740,317
JBrowse link
G Rps6kb1 ribosomal protein S6 kinase B1 multiple interactions ISO [PKI 166 co-treated with PD 173074] results in decreased activity of RPS6KB1 protein CTD PMID:15377668 NCBI chr10:71,323,777...71,367,908
Ensembl chr10:71,323,777...71,367,908
JBrowse link
G Src SRC proto-oncogene, non-receptor tyrosine kinase multiple interactions
decreases expression
ISO [Arsenic Trioxide co-treated with PD 173074] results in decreased expression of SRC protein; [Arsenic Trioxide results in increased susceptibility to PD 173074] which results in decreased expression of SRC protein; [PD 173074 results in increased susceptibility to Arsenic Trioxide] which results in decreased expression of SRC protein; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [[Arsenic Trioxide co-treated with PD 173074] results in decreased expression of SRC protein]; PD 173074 promotes the reaction [Arsenic Trioxide results in decreased expression of SRC protein modified form]; PD 173074 promotes the reaction [Arsenic Trioxide results in decreased expression of SRC protein]
PD 173074 results in decreased expression of SRC protein; PD 173074 results in decreased expression of SRC protein modified form
CTD PMID:27794399 NCBI chr 3:146,091,969...146,139,492
Ensembl chr 3:146,091,841...146,139,476
JBrowse link
G Tbx3 T-box transcription factor 3 multiple interactions ISO PD 173074 inhibits the reaction [afimoxifene results in increased expression of TBX3 protein]; PD 173074 inhibits the reaction [Estrogens results in increased expression of TBX3 protein] CTD PMID:21098263 NCBI chr12:36,879,924...36,894,849
Ensembl chr12:36,881,445...36,893,708
JBrowse link
G Vegfa vascular endothelial growth factor A multiple interactions ISO 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide promotes the reaction [PD 173074 inhibits the reaction [Sodium Chloride results in increased expression of VEGFA mRNA]]; PD 173074 inhibits the reaction [Sodium Chloride results in increased expression of VEGFA mRNA] CTD PMID:26800359 NCBI chr 9:14,955,300...14,970,641
Ensembl chr 9:14,955,300...14,970,641
JBrowse link

Term paths to the root
Path 1
Term Annotations click to browse term
  CHEBI ontology 20072
    role 20024
      biological role 20023
        pharmacological role 19105
          antagonist 16745
            fibroblast growth factor receptor antagonist 43
              2-amino-5-[(1-methoxy-2-methylindolizin-3-yl)carbonyl]benzoic acid 0
              AZD4547 6
              BGJ-398 0
              E-3810 0
              E-3810 free base 0
              PD173074 17
              SU5402 0
              brivanib + 0
              brivanib alaninate 0
              lenvatinib 19
              lenvatinib mesylate 0
              nintedanib 1
              nintedanib esylate 0
              sodium 2-amino-5-[(1-methoxy-2-methylindolizin-3-yl)carbonyl]benzoate 0
paths to the root